AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 61 min read$NTRA

RABINOWITZ DANIEL sold $90K of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 334 shares of Natera, Inc. (NTRA) at $267.99 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Aug 6, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the company’s Chief Legal Officer, including execution price and that it followed a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling optics, but the 10b5-1 structure makes this more of a routine disclosure than a catalyst.

03

What to watch

The article provides only the sale details; it does not include any offsetting buys, changes in guidance, or operational developments.

Relevance 2/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05 for a sale executed 2026-08-03.

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera Form 4 shows Daniel Rabinowitz, Chief Legal Officer, sold 334 shares at $267.9893 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing discloses the sale size, price, and that it was executed under a pre-arranged 10b5-1 plan, reducing the likelihood of an immediate information shock.

Market effects

Sector

No sector-level read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales can reflect routine liquidity planning rather than bearish expectations, so the market may ignore it.

Key entities

  • issuer
    Natera, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Daniel Rabinowitz

    Chief Legal Officer who sold 334 shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

timothysykes.com6 min
AUG 7
$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

benzinga.com4 min
AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min